Foote, J, Secord, AA, Liang, M, Cohn, DE, Jewell, E, and Havrilesky, LJ. "ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer." Journal of oncology practice 13, no. 12 (December 2017): e1030-e1039.
Angeles Alvarez Secord, MD
My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.
Education and Training
- Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
- M.D., University of Washington, 1994
- Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011
Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment.
Selected Grants and Awards
- Atezo NACT for Ovarian Cancer
- Lynparza Open Acess Olaparib
- GOG3015 Foundation Study ( Atezo Frontline)
- Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
- GOG3005-ABB VIE Protocol M13-694
- Quadra Study
- A Phase 2 Randomized Double-Blind Trial of Maintenance with Niraparib vs Placebo
- Apera ARP-407
- NCI National Clinical Trials Network U10 (Year 4)
- Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer
- Women with BRCA-mutated Advanced Stage Ovarian Cancer
- Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients
- Blood-based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer
- Tesaro Ovarian Cancer Practicum
- A Phase III Randomized, Double-Blind, Placebo Controlled Multicrentre Study of Olaparib Maintenance Monotherapy
Berchuck, A, Secord, AA, Moss, HA, and Havrilesky, LJ. "Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 36 (December 2017): 3999-4002.
Tanner, E, Puechl, A, Levinson, K, Havrilesky, LJ, Sinno, A, Secord, AA, Fader, AN, and Lee, PS. "Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer." Gynecologic oncology 147, no. 3 (December 2017): 535-540.
Johnson, OK, Berchuck, A, Secord, AA, and Peterson, AC. "Urinary diversion in the genitourinary cancer survivor." Gynecologic oncology (November 28, 2017). (Review)
Oliver, KE, Brady, WE, Birrer, M, Gershenson, DM, Fleming, G, Copeland, LJ, Tewari, K, Argenta, PA, Mannel, RS, Secord, AA, Stephan, J-M, Mutch, DG, Stehman, FB, Muggia, FM, Rose, PG, Armstrong, DK, Bookman, MA, Burger, RA, and Farley, JH. "An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience." Gynecologic oncology 147, no. 2 (November 2017): 243-249.
Phippen, NT, Secord, AA, Wolf, S, Samsa, G, Davidson, B, Abernethy, AP, Cella, D, Havrilesky, LJ, Burger, RA, Monk, BJ, and Leath, CA. "Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study." Gynecologic oncology 147, no. 1 (October 2017): 98-103.
von Gruenigen, VE, Huang, HQ, Beumer, JH, Lankes, HA, Tew, W, Herzog, T, Hurria, A, Mannel, RS, Rizack, T, Landrum, LM, Rose, PG, Salani, R, Bradley, WH, Rutherford, TJ, Higgins, RV, Secord, AA, and Fleming, G. "Chemotherapy Completion in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer—An NRG Oncology/Gynecologic Oncology Group Study." Obstetrical & Gynecological Survey 72, no. 8 (August 2017): 481-482.
Davidson, BA, Ehrisman, J, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Li, X, Havrilesky, LJ, and Hall, AHS. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer." International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists (July 11, 2017).
Winder, AD, Maniar, KP, Wei, J-J, Liu, D, Scholtens, DM, Lurain, JR, Schink, JC, Buttin, BM, Filiaci, VL, Lankes, HA, Ramirez, NC, Park, K, Singh, M, Lieberman, RW, Mannel, RS, Powell, MA, Backes, FJ, Mathews, CA, Pearl, ML, Secord, AA, Peace, DJ, Mutch, DG, Creasman, WT, and Kim, JJ. "Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study." Cancer 123, no. 7 (April 2017): 1144-1155.
von Gruenigen, VE, Huang, HQ, Beumer, JH, Lankes, HA, Tew, W, Herzog, T, Hurria, A, Mannel, RS, Rizack, T, Landrum, LM, Rose, PG, Salani, R, Bradley, WH, Rutherford, TJ, Higgins, RV, Secord, AA, and Fleming, G. "Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study." Gynecologic oncology 144, no. 3 (March 2017): 459-467.